Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia

Christian Joukhadar; Nikolas Klein; Mojgan Prinz; Claudia Schrolnberger; Thomas Vukovich; Michael Wolzt; Leopold Schmetterer; Guido T. Dorner

doi:10.1055/s-0037-1612902

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 85(01): 47-51
DOI: 10.1055/s-0037-1612902

Review Article

Schattauer GmbH

Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia

Autor*innen

Christian Joukhadar

¹Department of Clinical Pharmacology, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria
Nikolas Klein

¹Department of Clinical Pharmacology, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria
Mojgan Prinz

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria
Claudia Schrolnberger

¹Department of Clinical Pharmacology, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria
Thomas Vukovich

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria
Michael Wolzt

¹Department of Clinical Pharmacology, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria
Leopold Schmetterer

¹Department of Clinical Pharmacology, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria

³Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria
Guido T. Dorner

¹Department of Clinical Pharmacology, Institute of Medical Physics, University of Vienna Medical School, Vienna, Austria

Abstract

Summary

Background: Previous studies have suggested that statins exert beneficial effects beyond their favorable lipid lowering effect. Particularly, the modification of thrombus formation and degradation, alteration in inflammatory response, plaque stabilization and improved endothelial function are thought to be responsible for additional reduction of morbidity and mortality due to cardiovascular events. To date, however, it is still unclear whether these effects are elicited by all statins. Methods and Results: We set out to compare in a controlled, randomized, double-blind study design the effects of almost equieffective cholesterol lowering doses of three chemically and pharmacokinetically different statins (atorvastatin, simvastatin, pravastatin) on hemostatic and inflammatory markers in 99 hypercholesterolemic patients. At entry and 3 months after onset of statin therapy plasma cholesterol and von Willebrand factor antigen (vWf-Ag), fibrinogen, d-dimer, prothrombin fragment 1+2 (F1.2) and C-reactive protein (CRP) were measured. The effect on plasma values of F1.2, vWf-Ag, d-dimer and CRP was not significantly different between the three treatment groups. The effect of simvastatin on fibrinogen (p = 0.005) was more pronounced than the effects of atorvastatin (p = 0.48 n.s.) and pravastatin (p = 0.15 n.s.). Plasma levels of F1.2 and vWf-Ag (when data of all statins were pooled) were significantly reduced by 7% and 10% versus baseline, respectively. No significant reduction was observed for d-dimer (p = 0.26) and CRP (p = 0.5). Total plasma cholesterol levels decreased significantly (p <0.0001 in all groups) between 22% and 29% compared to baseline. Conclusion: The present study shows similar shortterm (3 months) effects of atorvastatin, simvastatin and pravastatin on selected hemostatic and inflammatory parameters in plasma in patients with hypercholesterolemia. Thus, chemical and pharmacological differences between statins appear to exert no major influence on these parameters.

Keywords

HMG-CoA reductase inhibitor - C-reactive protein - hemostatic factors

Volltext

Referenzen

References
1 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
2 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
3 Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92: 2419-25.
4 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
5 West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
6 Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
7 Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
8 Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7.
9 Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium dependent coronary vasomotion. N Engl J Med 1995; 332: 488-93.
10 Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-500.
11 Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in plasma cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
12 Furberg CD. Natural statins and stroke risk. Circulation 1999; 99: 185-8.
13 Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-25.
14 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
15 Stolley PD., Strom BL. Sample size calculations for clinical pharmacology studies. Clinical Pharmacology and Therapeutics 1986; 39: 489-90.
16 Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294-304.
17 Aoki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, Yanagisawa A, Yamamoto M, Kawai Y, Ishikawa K. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol 1997; 30: 91-6.
18 Black DM. Statins and fibrinogen. Lancet 1998; 351: 1430-1.
19 Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-72.
20 Haverkate F, Koopman J, de Maat MP. Statins and fibrinogen. Lancet 1998; 351: 1430-1.
21 Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet 1999; 353: 1274.
22 Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, Wilson SS, Lawson A, Peto R. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997; 18: 235-41.
23 Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-9.
24 Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351: 569-70.
25 Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-93.
26 Wada H, Mori Y, Kaneko T, Wakita Y, Minamikawa K, Ohiwa M, Tamaki S, Yokoyama N, Kobayashi T, Deguchi K, Shirakawa S, Suzuki K. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14: 829-34.
27 Ernst E. Fibrinogen as a cardiovascular risk factor – interrelationship with infections and inflammation. Eur Heart J 1993; 14 Suppl K 82-7.
28 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
29 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
30 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
31 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. for the ECAT. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
32 Jones P, Kafonek S, Laurona I, Hunninghake D. Comparative Dose Efficacy Study of Atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998; 81: 582-7.
33 Sinzinger H, Rodrigues M, Furberg CD. Dosing of atorvastatin and increases in fibrinogen level. Atherosclerosis 1999; 147: 421-2.
34 Blann AD, Maxwell SRJ, Burrows G, Miller JP. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis 1995; 16: 191-8.
35 Blann AD, Miller JP, McCollum CN. Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997; 32: 151-6.
36 Agewall S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J Hypertension 1998; 16: 537-41.